Manipulating the TME through therapeutics targeting the Treg/Th17 cell axis, such as monoclonal antibodies against TGF-β and IL-2, tyrosine kinase inhibitors like dasatinib, immunosuppressants such as tacrolimus, oncomicroRNA-based therapeutics and immune checkpoint inhibitors, holds promise for breast cancer immunotherapy (72). The gene discussed is IL2; the disease is breast carcinoma.